" class="no-js "lang="en-US"> Lumeon Commended by Frost & Sullivan for Enabling Digital Transformation in Healthcare - Medtech Alert
Monday, April 15, 2024

Lumeon Commended by Frost & Sullivan for Enabling Digital Transformation in Healthcare

Based on its recent analysis of the North American digital health market, Frost & Sullivan recognizes Lumeon with the 2021 North American Customer Value Leadership Award. Lumeon’s care journey orchestration platform and suite of solutions help health systems and providers automate digital care delivery. By automating communication, tasks, decisions and activities across patients and care teams, the platform allows health systems to reduce the burden on staff while offering comprehensive, convenient consumer experiences.

“Lumeon’s orchestration platform helps providers guide patients and care teams through a proactive and adaptive care plan, ensuring appropriate interventions at the right time,” said Srinath Venkatasubramanian, Industry Analyst, Transformational Health. “It acts as an agility layer for an electronic health record (EHR) system, extending workflow to wherever the patient is, with the ability to create continuous patient experiences and matching care team workflows from referral to recovery. By deeply integrating with the EHR, Lumeon ensures that all participants in the patient’s care journey have awareness of the patient’s current situation, status, issues and know the next best action, while keeping the health record up to date.”

Rather than only addressing siloed use cases, Lumeon’s solutions are designed to join up the care journey while automatically adapting it to address patients’ evolving situations. Its configurable orchestration engine proactively creates orders, schedules and tasks for care teams and engages patients on their own terms, personalizing the engagement to meet them where they are. These capabilities are core to any care journey because they provide patient context, optimize care, and prioritize deteriorating conditions.

The COVID-19 pandemic presented Lumeon with an opportunity to demonstrate the effectiveness of its technology and customer-centricity. The company launched COVID-19 rapid response solutions, such as screening tools, patient communications, and remote patient monitoring, in addition to other features, such as the instant delivery of COVID-19 test results and clinic virtual check-ins. Lumeon’s remote monitoring solution has allowed hospitals to screen and enroll symptomatic patients digitally into an intelligent COVID-19 home monitoring program, reducing pressure on emergency departments and enabling clinicians to focus on those most in need.

“Lumeon is intensifying focus on its orchestration engine because of the potential to quickly realize benefits for clients that not only adapt to their rapidly changing needs but are sustained for the long term” noted Venkatasubramanian. “The company is also remarkable for the depth of additional solutions used by its clients. This speaks to a company focused on building strong client relationships that contribute to its sustainable growth. Its solutions are currently deployed by more than 70 U.S.- and European-based clients.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers, with a focus on improving the return on the investment that customers make in its products and services. The award recognizes the company’s unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more